The role of inflammation in schizophrenia

Frontiers in Neuroscience

Volumn 9, Issue OCT, 2015, Pages

  Müller, Norbert ^a   Weidinger, Elif ^a   Leitner, Bianka ^a   Schwarz, Markus J ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

COX 2; Inflammation; Neuroinflammation; Psychoneuroimmunology; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MINOCYCLINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; RISPERIDONE; TRYPTOPHAN;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CHROMOSOME 6P; DISTRESS SYNDROME; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVATION; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; INFECTION; INFLAMMATION; MENTAL PATIENT; MICROGLIA; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; STRESS; TRYPTOPHAN METABOLISM;

EID: 84946567335     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00372     Document Type: Review

References (112)

1. Ahuja, N., and Carroll, B. T. (2007). Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 968-969. doi: 10.1016/j.pnpbp.2007.01.018
2. Anderson, G., Berk, M., Dodd, S., Bechter, K., Altamura, A. C., Dell'osso, B., et al. (2013). Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 1-4. doi: 10.1016/j.pnpbp.2012.10.008
3. Anisman, H., and Merali, Z. (2003). Cytokines, stress and depressive illness: brain-immune interactions. Ann. Med. 35, 2-11. doi: 10.1080/07853890310004075
4. Babulas, V., Factor-Litvak, P., Goetz, R., Schaefer, C. A., and Brown, A. S. (2006). Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am. J. Psychiatry 163, 927-929. doi: 10.1176/ajp.2006.163.5.927
5. Bechter, K., Bindl, A., Horn, M., and Schreiner, V. (2007). [Therapy-resistant depression with fatigue. A case of presumed streptococcal-associated autoimmune disorder]. Nervenarzt. 78, 338, 340-341. doi: 10.1007/s00115-006-2178-8
6. Benros, M. E., Mortensen, P. B., and Eaton, W. W. (2012). Autoimmune diseases and infections as risk factors for schizophrenia. Ann. N. Y. Acad. Sci. 1262, 56-66. doi: 10.1111/j.1749-6632.2012.06638.x
7. Benros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., and Mortensen, P. B. (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 168, 1303-1310. doi: 10.1176/appi.ajp.2011.11030516
8. Boksa, P. (2008). Maternal infection during pregnancy and schizophrenia. J. Psychiatry Neurosci. 33, 183-185.
9. Brown, A. S. (2008). The risk for schizophrenia from childhood and adult infections. Am. J. Psychiatry 165, 7-10. doi: 10.1176/appi.ajp.2007.07101637
10. Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., et al. (2004a). Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 61, 774-780. doi: 10.1001/archpsyc.61.8.774
11. Brown, A. S., Cohen, P., Greenwald, S., and Susser, E. (2000). Nonaffective psychosis after prenatal exposure to rubella. Am. J. Psychiatry 157, 438-443. doi: 10.1176/appi.ajp.157.3.438
12. Brown, A. S., Hooton, J., Schaefer, C. A., Zhang, H., Petkova, E., Babulas, V., et al. (2004b). Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161, 889-895. doi: 10.1176/appi.ajp.161.5.889
13. Brown, A. S., Schaefer, C. A., Quesenberry, C. P. Jr., Liu, L., Babulas, V. P., and Susser, E. S. (2005). Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 162, 767-773. doi: 10.1176/appi.ajp.162.4.767
14. Buka, S. L., Cannon, T. D., Torrey, E. F., and Yolken, R. H. (2008). Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol. Psychiatry 63, 809-815. doi: 10.1016/j.biopsych.2007.09.022
15. Buka, S. L., Tsuang, M. T., Torrey, E. F., Klebanoff, M. A., Bernstein, D., and Yolken, R. H. (2001). Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58, 1032-1037. doi: 10.1001/archpsyc.58.11.1032
16. Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186. doi: 10.1016/0893-133X(88)90012-7
17. Ceresoli-Borroni, G., Rassoulpour, A., Wu, H. Q., Guidetti, P., and Schwarcz, R. (2006). Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J. Neural Transm. 113, 1355-1365. doi: 10.1007/s00702-005-0432-z
18. Chakos, M. H., Schobel, S. A., Gu, H., Gerig, G., Bradford, D., Charles, C., et al. (2005). Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 186, 26-31. doi: 10.1192/bjp.186.1.26
19. Chaudhry, I. B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., et al. (2012). Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 26, 1185-1193. doi: 10.1177/0269881112444941
20. Chiveri, L., Sciacco, M., and Prelle, A. (2003). Schizophreniform disorder with cerebrospinal fluid PCR positivity for herpes simplex virus type 1. Eur. Neurol. 50, 182-183. doi: 10.1159/000073062
21. Claes, S., Myint, A. M., Domschke, K., Del-Favero, J., Entrich, K., Engelborghs, S., et al. (2011). The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res. 188, 355-360. doi: 10.1016/j.psychres.2011.03.012
22. Condray, R., Dougherty, G. G. Jr., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., et al. (2011). 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 14, 756-767. doi: 10.1017/S1461145710001689
23. Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K., and Perry, V. H. (2005). Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275-9284. doi: 10.1523/JNEUROSCI.2614-05.2005
24. Dalman, C., Allebeck, P., Gunnell, D., Harrison, G., Kristensson, K., Lewis, G., et al. (2008). Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry. 165, 59-65. doi: 10.1176/appi.ajp.2007.07050740
25. Dantzer, R. (2001). Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun. 15, 7-24. doi: 10.1006/brbi.2000.0613
26. Doorduin, J., de Vries, E. F., Willemsen, A. T., de Groot, J. C., Dierckx, R. A., and Klein, H. C. (2009). Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 50, 1801-1807. doi: 10.2967/jnumed.109.066647
27. Ellman, L. M., Deicken, R. F., Vinogradov, S., Kremen, W. S., Poole, J. H., Kern, D. M., et al. (2010). Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr. Res. 121, 46-54. doi: 10.1016/j.schres.2010.05.014
28. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L. H., and Engberg, G. (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96-98. doi: 10.1016/S0304-3940(01)02242-X
29. Felgenhauer, K. (1990). Psychiatric disorders in the encephalitic form of multiple sclerosis. J. Neurol. 237, 11-18. doi: 10.1007/BF00319661
30. Frank, M. G., Baratta, M. V., Sprunger, D. B., Watkins, L. R., and Maier, S. F. (2007). Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun. 21, 47-59. doi: 10.1016/j.bbi.2006.03.005
31. Furukawa, H., del Rev, A., Monge-Arditi, G., and Besedovsky, H. O. (1998). Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice. Ann. N. Y. Acad. Sci. 840, 117-122. doi: 10.1111/j.1749-6632.1998.tb09555.x
32. Gattaz, W. F., Abrahão, A. L., and Foccacia, R. (2004). Childhood meningitis, brain maturation and the risk of psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 254, 23-26. doi: 10.1007/s00406-004-0431-3
33. Genius, J., Geiger, J., Dölzer, A. L., Benninghoff, J., Giegling, I., Hartmann, A. M., et al. (2013). Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism. PLoS ONE 8:e59395. doi: 10.1371/journal.pone.0059395
34. Giovanoli, S., Engler, H., Engler, A., Richetto, J., Voget, M., Willi, R., et al. (2013). Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339, 1095-1099. doi: 10.1126/science.1228261
35. Godbout, J. P., and Johnson, R. W. (2009). Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol. Allergy Clin. North Am. 29, 321-337. doi: 10.1016/j.iac.2009.02.007
36. Goff, D. C. (2015). Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Curr. Opin. Psychiatry 28, 207-215. doi: 10.1097/YCO.0000000000000152
37. Gogtay, N., Lu, A., Leow, A. D., Klunder, A. D., Lee, A. D., Chavez, A., et al. (2008). Three-dimensional brain growth abnormalities in childhood-onset schizophrenia visualized by using tensor-based morphometry. Proc. Natl. Acad. Sci. U.S.A. 105, 15979-15984. doi: 10.1073/pnas.0806485105
38. Green, M. J., Girshkin, L., Teroganova, N., and Quidé, Y. (2014). Stress, schizophrenia and bipolar disorder. Curr. Top. Behav. Neurosci. 18:217-235. doi: 10.1007/7854_2014_290
39. Grüber, L., Bunse, T., Weidinger, E., Reichard, H., and Müller, N. (2014). Adjunctive recombinant human interferon gamma-1b for treatment-resistant schizophrenia in 2 patients. J. Clin. Psychiatry 75, 1266-1267. doi: 10.4088/jcp.14l09005
40. Hanson, D. R., and Gottesman, I. I. (2005). Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 6:7. doi: 10.1186/1471-2350-6-7
41. Hayley, S., Wall, P., and Anisman, H. (2002). Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms. Eur. J. Neurosci. 15, 1061-1076. doi: 10.1046/j.1460-9568.2002.01936.x
42. Hiroshi, H., Seiji, K., Toshihiro, K., and Nobuo, K. (2003). [An adult case suspected of recurrent measles encephalitis with psychiatric symptoms]. Seishin Shinkeigaku Zasshi. 105, 1239-1246.
43. Hohlfeld, R., Kerschensteiner, M., and Meinl, E. (2007). Dual role of inflammation in CNS disease. Neurology 68, S58-S63. doi: 10.1212/01.wnl.0000275234.43506.9b
44. Howes, O., McCutcheon, R., and Stone, J. (2015). Glutamate and dopamine in schizophrenia: an update for the 21st century. J. Psychopharmacol. 29, 97-115. doi: 10.1177/0269881114563634
45. Jarskog, L. F., Xiao, H., Wilkie, M. B., Lauder, J. M., and Gilmore, J. H. (1997). Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int. J. Dev. Neurosci. 15, 711-716. doi: 10.1016/S0736-5748(97)00029-4
46. Job, D. E., Whalley, H. C., McIntosh, A. M., Owens, D. G., Johnstone, E. C., and Lawrie, S. M. (2006). Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. BMC Med. 4:29. doi: 10.1186/1741-7015-4-29
47. Kabiersch, A., Furukawa, H., del Rey, A., and Besedovsky, H. O. (1998). Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice. Ann. N. Y. Acad. Sci. 840, 123-127. doi: 10.1111/j.1749-6632.1998.tb09556.x
48. Kegel, M. E., Bhat, M., Skogh, E., Samuelsson, M., Lundberg, K., Dahl, M. L., et al. (2014). Imbalanced kynurenine pathway in schizophrenia. Int. J. Tryptophan. Res. 7, 15-22. doi: 10.4137/IJTR.S16800
49. Kerbeshian, J., Burd, L., and Tait, A. (2007). Chain reaction or time bomb: a neuropsychiatric-developmental/neurodevelopmental formulation of tourettisms, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS. World J. Biol. Psychiatry 8, 201-207. doi: 10.1080/15622970601182652
50. Kerschensteiner, M., Meinl, E., and Hohlfeld, R. (2009). Neuro-immune crosstalk in CNS diseases. Neuroscience 158, 1122-1132. doi: 10.1016/j.neuroscience.2008.09.009
51. Körschenhausen, D. A., Hampel, H. J., Ackenheil, M., Penning, R., and Müller, N. (1996). Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res. 19, 103-109. doi: 10.1016/0920-9964(95)00073-9
52. Krause, D., Matz, J., Weidinger, E., Wagner, J., Wildenauer, A., Obermeier, M., et al. (2010). The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 11, 739-743. doi: 10.3109/15622971003653246
53. Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., et al. (2005). Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712. doi: 10.1093/brain/awh641
54. Laan, W., Grobbee, D. E., Selten, J. P., Heijnen, C. J., Kahn, R. S., and Burger, H. (2010). Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 71, 520-527. doi: 10.4088/JCP.09m05117yel
55. Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., et al. (2010). A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71, 138-149. doi: 10.4088/JCP.08m04666yel
56. Leweke, F. M., Gerth, C. W., Koethe, D., Klosterkötter, J., Ruslanova, I., Krivogorsky, B., et al. (2004). Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254, 4-8. doi: 10.1007/s00406-004-0481-6
57. Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M. L., Holtze, M., Engberg, G., et al. (2012). Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38, 426-432. doi: 10.1093/schbul/sbq086
58. Ling, Z. D., Potter, E. D., Lipton, J. W., and Carvey, P. M. (1998). Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp. Neurol. 149, 411-423. doi: 10.1006/exnr.1998.6715
59. Meinl, E., Krumbholz, M., Derfuss, T., Junker, A., and Hohlfeld, R. (2008). Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J. Neurol Sci. 274, 42-44. doi: 10.1016/j.jns.2008.06.032
60. Meisenzahl, E. M., Rujescu, D., Kirner, A., Giegling, I., Kathmann, N., Leinsinger, G., et al. (2001). Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am. J. Psychiatry 158, 1316-1319. doi: 10.1176/appi.ajp.158.8.1316
61. Mercadante, M. T., Busatto, G. F., Lombroso, P. J., Prado, L., Rosário-Campos, M. C., do Valle, R., et al. (2000). The psychiatric symptoms of rheumatic fever. Am. J. Psychiatry 157, 2036-2038. doi: 10.1176/appi.ajp.157.12.2036
62. Meyer, U., and Feldon, J. (2009). Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl). 206, 587-602. doi: 10.1007/s00213-009-1504-9
63. Meyer, U., Schwarz, M. J., and Müller, N. (2011). Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 132, 96-110. doi: 10.1016/j.pharmthera.2011.06.003
64. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., and Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70, 663-671. doi: 10.1016/j.biopsych.2011.04.013
65. Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., et al. (2008). Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl). 196, 233-241. doi: 10.1007/s00213-007-0955-0
66. Müller, N. (2010). COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs 11, 31-42.
67. Müller, N. (2014). Immunology of schizophrenia. Neuroimmunomodulation 21, 109-116. doi: 10.1159/000356538
68. Müller, N., and Bechter, K. (2013). The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurol. Psychiatry Brain Res. 19, 87-101. doi: 10.1016/j.npbr.2013.04.004
69. Müller, N., Gizycki-Nienhaus, B., Botschev, C., and Meurer, M. (1993). Cerebral involvement of scleroderma presenting as schizophrenia-like psychosis. Schizophr. Res. 10, 179-181. doi: 10.1016/0920-9964(93)90054-M
70. Müller, N., Gizycki-Nienhaus, B., Günther, W., and Meurer, M. (1992). Depression as a cerebral manifestation of scleroderma: immunological findings in serum and cerebrospinal fluid. Biol. Psychiatry 31, 1151-1156. doi: 10.1016/0006-3223(92)90160-2
71. Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., et al. (2010). Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 121, 119-124. doi: 10.1016/j.schres.2010.04.015
72. Müller, N., Myint, A. M., and Schwarz, M. J. (2011). Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr. Pharm. Des. 17, 130-136. doi: 10.2174/138161211795049552
73. Müller, N., Riedel, M., Schwarz, M. J., and Engel, R. R. (2005). Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 255, 149-151. doi: 10.1007/s00406-004-0548-4
74. Müller, N., and Schwarz, M. J. (2006). Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev. Neurother. 6, 1017-1038. doi: 10.1586/14737175.6.7.1017
75. Müller, N., and Schwarz, M. J. (2007). The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J. Neural. Transm. (Suppl. 72) 269-280. doi: 10.1007/978-3-211-73574-9_33
76. Müller, N., and Schwarz, M. J. (2010). Immune system and schizophrenia. Curr. Immunol. Rev. 6, 213-220. doi: 10.2174/157339510791823673
77. Myint, A. M., Schwarz, M. J., Verkerk, R., Mueller, H. H., Zach, J., Scharpé, S., et al. (2011). Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 25, 1576-1581. doi: 10.1016/j.bbi.2011.05.005
78. Nair, A., and Bonneau, R. H. (2006). Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 171, 72-85. doi: 10.1016/j.jneuroim.2005.09.012
79. Nikolich-Zugich, J. (2008). Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat. Rev. Immunol. 8, 512-522. doi: 10.1038/nri2318
80. Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J. M., et al. (2013). Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr. Bull. doi: 10.1093/schbul/sbt070
81. Notarangelo, F. M., Wilson, E. H., Horning, K. J., Thomas, M. A., Harris, T. H., Fang, Q., et al. (2014). Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr. Res. 152, 261-267. doi: 10.1016/j.schres.2013.11.011
82. Olsson, S. K., Andersson, A. S., Linderholm, K. R., Holtze, M., Nilsson-Todd, L. K., Schwieler, L., et al. (2009). Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int. J. Neuropsychopharmacol. 12, 501-512. doi: 10.1017/S1461145708009383
83. O'Neill, L. A. (2008). How frustration leads to inflammation. Science 320, 619-620. doi: 10.1126/science.1158398
84. Oommen, K. J., Johnson, P. C., and Ray, C. G. (1982). Herpes simplex type 2 virus encephalitis presenting as psychosis. Am. J. Med. 73, 445-448. doi: 10.1016/0002-9343(82)90751-3
85. Pearce, B. D. (2001). Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol. Psychiatry 6, 634-646. doi: 10.1038/sj.mp.4000956
86. Perry, V. H. (2007). Stress primes microglia to the presence of systemic inflammation: implications for environmental influences on the brain. Brain Behav. Immun. 21, 45-46. doi: 10.1016/j.bbi.2006.08.004
87. Potter, E. D., Ling, Z. D., and Carvey, P. M. (1999). Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res. 296, 235-246. doi: 10.1007/s004410051285
88. Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., and Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63, 801-808. doi: 10.1016/j.biopsych.2007.09.024
89. Rouse, B. T., and Sehrawat, S. (2010). Immunity and immunopathology to viruses: what decides the outcome? Nat. Rev. Immunol. 10, 514-526. doi: 10.1038/nri2802
90. Rutherford, B. R., Pott, E., Tandler, J. M., Wall, M. M., Roose, S. P., and Lieberman, J. A. (2014). Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 71, 1409-1421. doi: 10.1001/jamapsychiatry.2014.1319
91. Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., et al. (2011). Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37, 1147-1156. doi: 10.1093/schbul/sbq112
92. Schwarcz, R., Rassoulpour, A., Wu, H. Q., Medoff, D., Tamminga, C. A., and Roberts, R. C. (2001). Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50, 521-530. doi: 10.1016/S0006-3223(01)01078-2
93. Sommer, I. E., de Witte, L., Begemann, M., and Kahn, R. S. (2012). Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 73, 414-419. doi: 10.4088/JCP.10r06823
94. Sommer, I. E., van Westrhenen, R., Begemann, M. J., de Witte, L. D., Leucht, S., and Kahn, R. S. (2014). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40, 181-191. doi: 10.1093/schbul/sbt139
95. Sørensen, H. J., Mortensen, E. L., Reinisch, J. M., and Mednick, S. A. (2009). Association between prenatal exposure to bacterial infection and risk of schizophrenia. Schizophr. Bull. 35, 631-637. doi: 10.1093/schbul/sbn121
96. Sparkman, N. L., and Johnson, R. W. (2008). Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation 15, 323-330. doi: 10.1159/000156474
97. Sperner-Unterweger, B., Barnas, C., Fuchs, D., Kemmler, G., Wachter, H., Hinterhuber, H., et al. (1992). Neopterin production in acute schizophrenic patients: an indicator of alterations of cell-mediated immunity. Psychiatry Res. 42, 121-128. doi: 10.1016/0165-1781(92)90076-F
98. Steen, R. G., Mull, C., McClure, R., Hamer, R. M., and Lieberman, J. A. (2006). Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 188, 510-518. doi: 10.1192/bjp.188.6.510
99. Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H. G., Vielhaber, S., et al. (2013). Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70, 271-278. doi: 10.1001/2013.jamapsychiatry.86
100. Stone, T. W. (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 309-379.
101. Takano, A., Arakawa, R., Ito, H., Tateno, A., Takahashi, H., Matsumoto, R., et al. (2010). Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol. 13, 943-950. doi: 10.1017/S1461145710000313
102. Teixeira, A. L. Jr., Maia, D. P., and Cardoso, F. (2007). Psychosis following acute Sydenham's chorea. Eur. Child Adolesc. Psychiatry 16, 67-69. doi: 10.1007/s00787-006-0566-z
103. van Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., et al. (2008). Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 64, 820-822. doi: 10.1016/j.biopsych.2008.04.025
104. van Dam, A. P. (1991). Diagnosis and pathogenesis of CNS lupus. Rheumatol. Int. 11, 1-11. doi: 10.1007/BF00290244
105. Versijpt, J. J., Dumont, F., van Laere, K. J., Decoo, D., Santens, P., Audenaert, K., et al. (2003). Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 50, 39-47. doi: 10.1159/000070857
106. Vincent, A., and Bien, C. G. (2008). Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol. 7, 1074-1075. doi: 10.1016/S1474-4422(08)70225-4
107. Westergaard, T., Mortensen, P. B., Pedersen, C. B., Wohlfahrt, J., and Melbye, M. (1999). Exposure to prenatal and childhood infections and the risk of schizophrenia: suggestions from a study of sibship characteristics and influenza prevalence. Arch. Gen. Psychiatry 56, 993-998. doi: 10.1001/archpsyc.56.11.993
108. Wildenauer, D. B., Körschenhausen, D., Hoechtlen, W., Ackenheil, M., Kehl, M., and Lottspeich, F. (1991). Analysis of cerebrospinal fluid from patients with psychiatric and neurological disorders by two-dimensional electrophoresis: identification of disease-associated polypeptides as fibrin fragments. Electrophoresis 12, 487-492. doi: 10.1002/elps.1150120706
109. Winter, C., Djodari-Irani, A., Sohr, R., Morgenstern, R., Feldon, J., Juckel, G., et al. (2009). Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int. J. Neuropsychopharmacol. 12, 513-524. doi: 10.1017/S1461145708009206
110. Yolken, R. H., and Torrey, E. F. (1995). Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 8, 131-145.
111. Zhou, D., Kusnecov, A. W., Shurin, M. R., DePaoli, M., and Rabin, B. S. (1993). Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 133, 2523-2530.
112. Zubin, J., and Spring, B. (1977). Vulnerability-a new view of schizophrenia. J. Abnorm. Psychol. 86, 103-126. doi: 10.1037/0021-843X.86.2.103